Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Anemia, Neoplasms, Chemotherapeutic-Induced Anemia

About this trial
This is an interventional treatment trial for Anemia focused on measuring children, anemia, chemotherapy treatment, quality of life, erythropoietin
Eligibility Criteria
Inclusion Criteria: Children between 2-17 years old Hemoglobin <12g/dL Solid tumors without bone metastasis Being on current chemotherapy treatment Adequate serum levels of iron, folic acid and Vitamin B12 Signature of the Free and Informed Consent Form by the person responsible and Term of Assent by the patient Exclusion Criteria: Refusal to sign the Free and Informed Consent Form and/or Term of assent Estimated survival less than 12 weeks Previous adverse reactions associated with EPO Estar em uso de EPO e inibidores do fator de indução de hipóxia.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention group
Control Group
Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between <12g/dL. Every week (1 to 12), the study medication will be administered 3 times, according to the proposed treatment, for those allocated in the intervention group. All assessments, procedures and notes must be recorded in a source document and in a CRF.
For the control group, the procedures will be performed according to the institution's standard treatment (Vitamin B12 and folic acid). The use of Iron, Vitamin B12 and folic acid will be allowed both in the intervention arm and in the control arm. Doses should be prescribed at the physician's discretion.